Hong DS. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1). Presented at: 32nd EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. October 24-25, 2020.
Hong DS. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1). Presented at: 32nd EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. October 24-25, 2020.